首页>
外国专利>
New substituted dihydropyrazolthione compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat or prevent e.g. heart insufficiency, anemia, chronic kidney diseases and renal failure
New substituted dihydropyrazolthione compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat or prevent e.g. heart insufficiency, anemia, chronic kidney diseases and renal failure
Substituted dihydropyrazolthione compounds (I) and their salts, solvates and solvate of the salts, are new, where (I) excludes 3-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-pyridin-2-yl-1H-pyrazol-5-thiol. Substituted dihydropyrazolthione compounds of formula (I) and their salts, solvates and solvate of the salts, are new, where (I) excludes 3-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-pyridin-2-yl-1H-pyrazol-5-thiol. R1, R2nitrogen containing heteroaryl groups; and R3H, 1-6C alkyl or 3-7C cycloalkyl. Full Definitions are given in the DEFINITIONS (Full Definitions) Field. Independent claims are included for: (1) preparation of (I); and (2) a medicament comprising (I) in combination with an inert, non-toxic, pharmaceutical auxiliary material. [Image] ACTIVITY : Cardiovascular-Gen; Cardiant; Antianemic; Antidiabetic; Vasotropic; Nephrotropic; Neuroprotective; Endocrine-Gen; Anabolic; Ophthalmological; Antiparkinsonian; Nootropic; Analgesic; Vulnerary; Cytostatic; Antianginal; Cerebroprotective; Antiarteriosclerotic; Hypotensive; Antiinflammatory; Antimicrobial; Gastrointestinal-Gen.; Antiarthritic; Antirheumatic. MECHANISM OF ACTION : Hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitor. Tests details are described but no results given.
展开▼
